We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | AQSE:IMM.GB | Aquis Stock Exchange | Ordinary Share | GB0033711010 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.55 | -21.57% | 2.00 | 1.50 | 2.50 | 2.55 | 2.00 | 2.55 | 464,916 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIMM
RNS Number : 5484N
Immupharma PLC
26 October 2016
RNS : FOR IMMEDIATE RELEASE 26 OCTOBER 2016
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.
Full disclosure of the TR1 is shown below:
-Ends-
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Panmure, Gordon & Co., (NOMAD +44 (0) 20 & Broker) 7886 2500 Freddy Crossley, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, John Howes, Corporate +44 (0)20 3861 Broking 6631 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) -------------------------------------------------- 1. Identity of the issuer or Immupharma plc the underlying issuer of existing shares to which voting rights are attached: (ii) ----------------------------------------------------------- --------------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ---------------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights x ------------------------------------------------------------------------------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------------------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------------------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------------------------------------ Other (please The placement by ImmuPharma PLC of x specify): 2,857,143 new ordinary shares ---------------------------------------------------------- ------------------------------------ 3. Full name of person(s) Lanstead Capital LP subject to the notification obligation: (iii) ----------------------------------------------------------- --------------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- --------------------------------------- 5. Date of the transaction 21 October 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- --------------------------------------- 6. Date on which issuer 25 October 2016 notified: ----------------------------------------------------------- --------------------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 14%, 13%, 12%, 11%, 10%, 9% ----------------------------------------------------------- --------------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- ------------- --------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- ------------- ------------- ------------ ------------ ----------- GB0033711010 17,893,456 17,893,456 10,521,555 10,521,555 8.44% --------------- --------------- ------------- ------------- ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------ ----------------------------- --------------------- N/A ----------------- ------------- ------------------------------ ----------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- --------------- ----------------------------- ----------------------- N/A Nominal Delta --------------- ------------- ------------- --------------- ----------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 10,521,555 8.44% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ---------------------------------------------------------------------------------------- N/A Proxy Voting: ---------------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ------------------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ------------------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ------------------------- 13. Additional information: ------------------------------------------------------------- ------------------------- 14. Contact name: Lisa De Vargas, Lanstead Partners Limited ------------------------------------------------------------- ------------------------- 15. Contact telephone number: +1 (801) 895-3700
------------------------------------------------------------- -------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLZQLFLQBFXFBQ
(END) Dow Jones Newswires
October 26, 2016 10:42 ET (14:42 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions